Ascendis Pharma A/S (ASND) to Post FY2017 Earnings of ($4.25) Per Share, Wedbush Forecasts

Ascendis Pharma A/S (NASDAQ:ASND) – Equities researchers at Wedbush lowered their FY2017 earnings estimates for shares of Ascendis Pharma A/S in a report issued on Wednesday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will earn ($4.25) per share for the year, down from their prior forecast of ($3.58). Wedbush has a “Outperform” rating and a $10.71 price objective on the stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2017 earnings at ($1.00) EPS, Q1 2018 earnings at ($1.01) EPS, Q2 2018 earnings at ($1.03) EPS, Q3 2018 earnings at ($1.05) EPS, Q4 2018 earnings at ($1.07) EPS, FY2018 earnings at ($4.17) EPS, FY2019 earnings at ($5.13) EPS, FY2020 earnings at ($4.52) EPS and FY2021 earnings at ($0.37) EPS.

Several other analysts have also recently commented on the stock. Bank of America reduced their price objective on shares of Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, November 17th. Wells Fargo & Company reiterated a “buy” rating and issued a $51.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Credit Suisse Group reiterated an “outperform” rating and issued a $50.00 price objective (up previously from $30.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Leerink Swann reiterated a “hold” rating and issued a $28.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Finally, Zacks Investment Research cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $36.45.

Shares of Ascendis Pharma A/S (ASND) opened at $36.91 on Monday. Ascendis Pharma A/S has a 52 week low of $19.21 and a 52 week high of $42.00.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management LLC raised its position in Ascendis Pharma A/S by 3.2% during the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock worth $154,920,000 after acquiring an additional 170,700 shares during the last quarter. EcoR1 Capital LLC raised its position in Ascendis Pharma A/S by 44.5% during the second quarter. EcoR1 Capital LLC now owns 1,482,600 shares of the biotechnology company’s stock worth $41,157,000 after acquiring an additional 456,900 shares during the last quarter. VHCP Management II LLC raised its position in Ascendis Pharma A/S by 31.7% during the third quarter. VHCP Management II LLC now owns 1,299,052 shares of the biotechnology company’s stock worth $47,091,000 after acquiring an additional 312,560 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Ascendis Pharma A/S during the second quarter worth about $15,403,000. Finally, First Manhattan Co. acquired a new position in Ascendis Pharma A/S during the third quarter worth about $12,881,000. Institutional investors own 78.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ascendis Pharma A/S (ASND) to Post FY2017 Earnings of ($4.25) Per Share, Wedbush Forecasts” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/04/ascendis-pharma-as-asnd-to-post-fy2017-earnings-of-4-25-per-share-wedbush-forecasts.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply